GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Cash-to-Debt

SI-BONE (SI-BONE) Cash-to-Debt : 4.26 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SI-BONE's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SI-BONE could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for SI-BONE's Cash-to-Debt or its related term are showing as below:

SIBN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.58   Med: 2.8   Max: 4.98
Current: 4.26

During the past 8 years, SI-BONE's highest Cash to Debt Ratio was 4.98. The lowest was 0.58. And the median was 2.80.

SIBN's Cash-to-Debt is ranked better than
62.06% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs SIBN: 4.26

SI-BONE Cash-to-Debt Historical Data

The historical data trend for SI-BONE's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SI-BONE Cash-to-Debt Chart

SI-BONE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial 2.34 4.98 3.63 2.47 4.26

SI-BONE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.16 4.28 4.24 4.26

Competitive Comparison of SI-BONE's Cash-to-Debt

For the Medical Devices subindustry, SI-BONE's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SI-BONE's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SI-BONE's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SI-BONE's Cash-to-Debt falls into.



SI-BONE Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SI-BONE's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

SI-BONE's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SI-BONE  (NAS:SIBN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


SI-BONE Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SI-BONE's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


SI-BONE (SI-BONE) Business Description

Traded in Other Exchanges
N/A
Address
471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Executives
Anshul Maheshwari officer: Chief Financial Officer 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero officer: Chief Commercial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn director, officer: Chairman, President & CEO C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis officer: Chief Financial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky officer: GC & Chief Compliance Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh director 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp 10 percent owner 525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling officer: CMO and VP, Medical Affairs C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby officer: Chief Technology Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451